Skip to main content

Table 1 Clinicopathological characteristics of the 62 patients dichotomized by exon19 microdeletions and exon21 mutations

From: Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

  Total Exon19 Exon21 p-value
Number of patients 62 (100%) 37 (66.1%) 25 (33.9%)  
Age (median, range) 70.5 (28–86) 67 (28–81) 71 (48–86) 0.088
Gender Male 12 (19.4%) 8 (21.6%) 4 (16%) 0.747
Female 50 (80.6%) 29 (78.4%) 21 (84%)
ECOG performance status 0 24 (38.7%) 17(46%) 7(28%) 0.182
1 32 (51.6%) 17(46%) 15(60%)
2 6(9.7%) 3(8%) 3 (12%)
Smoking status Never-smoker 42(67.7%) 25 (67.5%) 17 (68%) 1.00
Ever smoker 20(32.3%) 12 (32.5%) 8 (32%)
Tumor Stage IIIb 6 (9.7%) 1 (1.6%) 5(20%) 0.035
IV 56 (90.3%) 36(98.4%) 20(80%)
  1. Data shown in parentheses are column percentages;